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ABSTRACT
Global guidelines for new technologies are based on cost and efﬁcacy data from a limited number of trial locations.
Country-level decision makers need to consider whether cost-effectiveness analysis used to inform global guidelines are
sufﬁcient for their situation or whether to use models that adjust cost-effectiveness results taking into account setting-
speciﬁc epidemiological and cost heterogeneity. However, demand and supply constraints will also impact cost-
effectiveness by inﬂuencing the standard of care and the use and implementation of any new technology. These constraints
may also vary substantially by setting. We present two case studies of economic evaluations of the introduction of new di-
agnostics for malaria and tuberculosis control. These case studies are used to analyse how the scope of economic evaluations of
each technology expanded to account for and then address demand and supply constraints over time. We use these case studies
to inform a conceptual framework that can be used to explore the characteristics of intervention complexity and the inﬂuence of
demand and supply constraints. Finally, we describe a number of feasible steps that researchers who wish to apply our
framework in cost-effectiveness analyses.
KEY WORDS: economic evaluation; health system; demand; health technology assessment
1. INTRODUCTION
As new health technologies are developed, the World Health Organisation (WHO; 2012) considers whether to
revise its guideline recommendations. Evidence on efﬁcacy, cost and, in some cases, cost-effectiveness may
inform these revisions. Country-level decision makers need to consider whether to adopt revised guidelines
and fund the introduction of new technologies (Nasser et al., 2014). Countries may consider the results of eco-
nomic evaluations performed to inform global guidelines. However, unlike efﬁcacy, cost-effectiveness analyses
are not necessarily generalisable beyond a speciﬁc setting (Drummond et al., 2005). In theory, each country
could conduct its own economic evaluation. However, in practice, such country-speciﬁc analyses may be con-
sidered too time-consuming and expensive for the majority of low-income and middle-income countries
(LMICs). To support the rapid scale-up of new technologies, global health actors have therefore invested in de-
veloping user-friendly models that enable decision makers in LMICs to assess the cost-effectiveness of intro-
ducing a given new technology in their own setting (Lubell et al., 2008a; Winfrey et al., 2011; Pretorius
et al., 2014a; Pretorius et al., 2014b).
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Multi-country cost-effectiveness models typically apply efﬁcacy data from trials and adjust for heteroge-
neity in demography, epidemiology, and unit costs (Lubell et al., 2008a; Winfrey et al., 2011; Pretorius
et al., 2014a; Pretorius et al., 2014b). Unit costs are adjusted either through cost models (using an ingre-
dients approach and local input prices) or by using statistical models to extrapolate costs from empirical
studies conducted in other settings. Cost and efﬁcacy data are commonly entered as uncorrelated parame-
ters. It is, however, rare for these models to explicitly consider other setting-speciﬁc inﬂuences on cost-
effectiveness in LMICs, despite the fact that literature from high-income countries (HICs) identiﬁes a wide
range of factors that are important to consider when transferring cost-effectiveness estimates between set-
tings (Drummond et al., 2009). In particular, the use and therefore cost-effectiveness of new technologies
may be adversely inﬂuenced by constraints to the demand for and supply of health services in which the
technology is placed.
This paper aims to encourage the consideration and incorporation of supply and demand constraints in
economic evaluations of new health technologies in LMICs. Our objectives are threefold: ﬁrst, to highlight
the importance of considering constraints; second, to conceptualise constraints; and third, to propose pragmatic
options for incorporating these constraints in economic evaluations. We begin by presenting a review of
economic evaluations of new diagnostics for malaria and tuberculosis (TB) control and describe the extent to
which these economic evaluations have considered demand and supply constraints and how these constraints
inﬂuenced results. These two case studies are then used to develop a conceptual framework for identifying
demand and supply constraints. Finally, we discuss the options and challenges in applying this framework
going forward.
2. ECONOMIC EVALUATIONS OF RAPID DIAGOSTIC TESTS FOR MALARIA AND
TUBERCULOSIS
In this section, we describe how the scope of economic evaluations conducted on new diagnostics for
malaria and TB control evolved to incorporate demand and supply constraints. For this review, we
broadly define ‘demand constraints’ as factors that restrict the individual’s ability to seek and use
healthcare services in a way that maximises the individual’s utility. ‘Supply constraints’ are defined as
factors that restrict the provider’s ability to provide these services efficiently and with sufﬁcient coverage
and quality to have an optimal impact. We examine constraints that are additional to a payer’s budget
constraints.
In the case of malaria, we examine rapid diagnostic tests (mRDTs) at point of care. Prior to the rollout of
mRDTs, most individuals with suspected malaria had limited access to facilities with microscopy (the previous
standard of care) and were treated presumptively. Deploying mRDTs has the potential to reduce the
overprovision of expensive anti-malarials and to improve the clinical management of non-malaria febrile ill-
nesses. In the case of TB, we examine the implementation of Xpert MTB/RIF (hereafter referred to as Xpert),
a test with improved sensitivity compared with microscopy (the previous standard of care) particularly for those
co-infected with HIV and TB (Boehme et al., 2011). Xpert is also able to identify potential cases of multi-drug-
resistant TB (MDR-TB).
To identify economic evaluations on mRDTs, we searched PubMed, Scopus and the NHS Economic
Evaluation Database for the terms ‘malaria’ and ‘cost’ and ‘rapid diagnostic’. Citations and bibliographies
of studies retrieved and WHO malaria guidelines were reviewed for additional articles published between
January 2004 and September 2015. For Xpert, we used two systematic reviews, one of modelling studies
of novel diagnostic strategies for TB (Zwerling et al., 2014) and one of TB control costs (Laurence
et al., 2015) and then updated them through a PubMed search for the terms ‘tuberculosis’ and ‘cost’ and
‘Xpert’. Citations and bibliographies of studies retrieved were reviewed for additional articles published
up until September 2015.
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We identiﬁed 27 economic evaluations on mRDTs and 10 economic evaluations on Xpert MTB/RIF (Table I).
We categorise them into three groups, according to the way in which they consider demand and supply constraints:
A. No adjustment. Economic evaluations that include attributes of the new technology (such as test
accuracy/efﬁcacy), setting-speciﬁc unit costs, and/or epidemiological considerations (such as disease
prevalence) only.
B. Adjust for constraints. Economic evaluations that include parameters listed in group A and also explore
the inﬂuence of setting-speciﬁc demand and supply constraints (such as care-seeking preferences,
patient adherence to treatment and/or provider practice).
C. Address constraints. Economic evaluations that include parameters listed in groups A and B and also
consider interventions to address demand and/or supply constraints (such as provider training, patient
education and/or incentives).
A. Economic evaluations that do not adjust for demand and supply constraints
Half (14 of 27) of the economic evaluations conducted on mRDT did not adjust for any demand or supply
constraints (Table I). Diagnosis using mRDTs is compared with presumptive diagnosis, microscopy or both,
and the studies include parameters on the accuracy of the alternative diagnostic methods, combined with
setting-speciﬁc data on unit costs of diagnosis and treatment and the prevalence of malaria. The cost-
effectiveness of mRDTs and microscopy varied across the studies and was inﬂuenced by setting-speciﬁc unit
costs and prevalence. While demand and supply constraints were not investigated directly, some studies noted
that their ﬁndings were dependent on assumptions made regarding the ‘ﬁeld’ accuracy of microscopy, pre-
scribers’ use of test results and patients’ adherence to treatment.
In the case of Xpert, four of the 10 economic evaluations did not explicitly consider supply or demand con-
straints. In a similar manner to the studies on mRDTs, these studies considered unit costs and difference in
epidemiology by setting. While there was no explicit consideration of any constraints, some studies included
costs for training and quality control of Xpert (Vassall et al., 2011). Sensitivity analyses were also conducted
around the performance of other tests in the diagnostic pathway and the level of HIV care coverage, but no con-
straints on either provider or patient adherence to the TB diagnostic or the treatment pathway were considered
(Abimbola et al., 2012; Andrews et al., 2012; Menzies et al., 2012).
B. Economic evaluations that adjust for potential demand and supply constraints
Ten of the economic evaluations conducted on mRDTs explicitly adjusted for demand and supply con-
straints. One of the ﬁrst studies explored how provider behaviour can impact on the cost-effectiveness of
mRDTs using trial data from Tanzania (Lubell et al., 2008b). The authors concluded that neither mRDTs
nor microscopy would be beneﬁcial given the high rate at which anti-malarials were prescribed to patients
who tested negative for malaria. This study found that costs incurred would be 10–250% higher (depending
on transmission rate) than if prescribing practice were fully consistent with test results. Similar ﬁndings were
reported in Kenya, where an economic model populated with observed data on provider practice found that in-
troducing mRDTs in a low transmission area would incur 41% higher costs and achieve only a small reduction
in under-treatment errors than the standard of care (Zurovac et al., 2008). Other studies investigated the sensi-
tivity of ﬁndings to the locally achieved accuracy of microscopy (Harchut et al., 2013).
In the case of Xpert, this category contains two sub-categories of studies. In the ﬁrst set are three studies, which
considered how the organisation of health services may affect the cost-effectiveness of Xpert. These studies ex-
plored how the placement of Xpert in sites with different workloads inﬂuenced costs (Meyer-Rath et al., 2011),
the availability and use of other diagnostic tests (van’t Hoog et al., 2013) and capacity constraints at the facility
and district level (Lin et al., 2011). The second category of studies evaluate the cost-effectiveness of Xpert during
scale-up in ‘early adopter’ countries using large-scale pragmatic trials. Preliminary results from these studies
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suggested that effective presumptive TB treatment, lack of access to HIV treatment, high levels of default from
the diagnostic process and poor adherence by both clinicians and patients to guidelines following negative test
results may substantially reduce the cost-effectiveness of Xpert (Theron et al., 2014a; Theron et al., 2014b;
Churchyard et al., 2015). When the results of these trials were taken into consideration, estimates of incremen-
tal cost-effectiveness ratios (ICERs) for a range of settings increased by up to 60% (Menzies et al., 2015).
C. Economic evaluations that address demand and supply constraints
Three of the economic evaluations on mRDTs extended the scope of the ‘mRDT’ intervention to include
activities to address demand and supply constraints. For example, in Cameroon, an economic evaluation
assessed the introduction of mRDTs with two types of provider training: basic training on revised malaria
guidelines and an enhanced training, which supplied information on the guidelines and targeted provider be-
haviour (Mangham-Jefferies et al., 2014). The study showed that introducing mRDTs with enhanced training
was more expensive than mRDTs with basic training, but also more cost-effective. In Myanmar, researchers
evaluated four strategies for introducing mRDTs and concluded that introducing subsidised RDTs in the private
sector accompanied by information, education and communication (IEC) and/or a combination of IEC and
ﬁnancial incentives would be cost-effective (Chen et al., 2015).
Only one Xpert study has analysed the cost-effectiveness of activities to address supply or demand constraints.
This study examined the combined cost-effectiveness of Xpert with activities to support adherence to the diagnos-
tic algorithm (follow-up of those defaulting, follow-up of negative test results in those with HIV and linkage to
HIV care) in South Africa and found much higher ICERs than originally predicted (Foster et al., 2015).
In summary, our case studies suggest that failing to consider demand and supply constraints may overesti-
mate cost-effectiveness. Although these case studies do not represent the vast array of new technologies in all
LMICs, they are particularly important cases given the substantial investments being made in rapid diagnostics.
The inclusion of constraints in both cases substantially inﬂuenced estimates of ICERs, and this suggests that
constraints should be routinely considered in economic evaluations, at least to the same extent as heterogeneity
in epidemiology is considered across settings. It could be argued that evaluating new technologies in the con-
text of demand and supply constraints may ‘unfairly’ penalise new technologies for factors that are outside their
control. However, including the cost of activities that address constraints (or reducing the estimated effect in
their absence) rewards more feasible technologies, which is the primary innovation for many new technologies
designed for use in LMIC’s. As a decision and policy-oriented ﬁeld, economic evaluation is concerned with
minimising the actual opportunity cost in the decision makers’ jurisdiction, rather than a hypothetical one.
3. CONCEPTUAL FRAMEWORK
Informed by the case studies, we consider two approaches to incorporate demand and supply constraints in eco-
nomic evaluations. The ﬁrst is to view the technology and activities to address constraints (sometimes referred
to as ‘critical enablers’ (Schwartlander et al., 2011)) as distinct interventions and to assess their cost-
effectiveness separately. This approach is analogous to those distinguishing between the efﬁcacy of a technol-
ogy and its effectiveness during implementation in the clinical literature and underpins the economic evaluation
approach taken in our case studies (ﬁrst evaluate based on efﬁcacy, then examine the incremental cost-
effectiveness of supporting activities).
Alternatively, we propose that researchers should start from the perspective that new technologies are not ‘in-
terventions’ in themselves. Many new technologies will require some supporting activity to achieve satisfactory
efﬁcacy and coverage objectives, given the extensive demand and supply side constraints in LMICs. We recom-
mend that researchers should therefore routinely assume that the introduction of new technologies is likely to be
an inherently complex intervention with many component activities. There is a substantive literature on how to de-
termine whether an intervention is complex (Hawe et al., 2004; Shiell et al., 2008). In general, complex interven-
tions are characterised as having several interacting activities and typically require those delivering or receiving the
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intervention to modify their behaviour. We accept that not all new technologies will fulﬁl these criteria. The extent
to which introducing a new technology requires a complex intervention may depend on the nature of the technol-
ogy, the extent of constraints, and the scale of the technology required. However, we propose that, given the extent
of constraints, complexity needs to be ‘ruled out’ rather than ‘ruled in’ in economic evaluations in LMICs.
To assist in this process, we outline in the succeeding discussions a framework for researchers ﬁrstly to de-
ﬁne the intervention they are evaluating and thereafter to guide their economic evaluation design. Some argue
that while complexity may raise additional questions, with adequate time and resources, existing economic
evaluation frameworks remain appropriate (Shiell et al., 2008). However, in the case of economic evaluation
in LMICs, the extensive task of characterising, identifying and modelling intervention complexity remains a
barrier for widespread global application.
Previous work on transferability frameworks from high-income country (HIC) settings identiﬁes a range of
factors that inﬂuence economic evaluation results by setting, including patient, clinician, healthcare system and
wider socio-economic factors (Sculpher et al., 2004; Drummond et al., 2005). The ISPOR Good Research
Practice Task Force report on the ‘Transferability of Economic Evaluations across Jurisdictions’ also identiﬁes
similar considerations (Drummond et al., 2009). Many of these setting-speciﬁc determinants of cost-
effectiveness fall within our deﬁnition of demand and supply constraints in the context of LMICs. There is also
a body of literature from health systems research assessing the relationships between various new technologies,
the health system and patient outcomes (Atun et al., 2010a; Atun et al., 2010b); a number of frameworks such
as the WHO’s ‘Building Blocks’ that provide insight into the range of supply constraints; and conceptual
frameworks examining demand-side constraints for health services (Levesque et al., 2013).
Building on this work, in Figure 1, we present a visual conceptual framework to help researchers identify
demand and supply constraints. This conceptualisation promotes a comprehensive description of the interven-
Figure 1. Conceptual framework for identifying the intervention and constraints in the context of the disease/illness/care pathway
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tion, including the technology and activities to support its optimal use. The disease/illness/care pathway lies at
the centre of the conceptual framework. We depict a simple disease/illness/care pathway that starts from onset
of symptoms and continues to care seeking, diagnosis, treatment offered and treatment taken. This form of
pathway needs to be speciﬁed in sufﬁcient detail to include both disease progression and key decisions taken
to seek/provide care. Additional stages could be added, for example, if the diagnostic process involved multiple
sequential tests.
Having speciﬁed the pathway, including key decision points and options at each stage, the next step is to
consider (i) how key decision points to seek/provide care are inﬂuenced by the new technology, (ii) the extent
to which decisions/options are likely to be constrained by demand and supply factors, and (iii) what actions are
needed to address these demand or supply constraints. Specifying the theory of change (De Silva et al., 2014)
outlining how the new technology is expected to impact the pathway and outcomes may help in this task.
Some constraints on decision points in the pathway may only become apparent as new technologies are
scaled up and may go beyond a direct inﬂuence on the technology. For example, while suboptimal provider
behaviour may be noticeable at low coverage, more general, human resource constraints may only become ap-
parent at scale. Likewise, on the demand side, uptake of a new technology may be relatively straightforward for
users who are frequent health service attendees, but there may be additional costs of ensuring access to hard-to-
reach groups at higher levels of scale. We have therefore sought to distinguish proximal and distal constraints in
our framework. On the demand side, proximal constraints include those that directly restrict access, uptake or
adherence to the optimal patient pathway. For instance, care seeking may depend on the ease and cost of
accessing care, individuals’ awareness of symptoms and treatment options and perceptions about the quality
of care. These proximal constraints are in turn inﬂuenced by household economics and underlying values
and preferences that are shaped by the economic, social and cultural context. On the supply side, proximal con-
straints may include the knowledge and behaviour of healthcare providers and the availability of complemen-
tary resources and services. However, these may be constrained by distal factors, such as overall human
resource availability; mechanisms for healthcare ﬁnancing, planning and management; and the functioning
of private sector providers.
We demonstrate how the conceptual framework can be used by applying it to the introduction of mRDTs
(Table II). The ﬁrst column of Table II depicts the different stages in the pathway, and the subsequent
columns then consider (i) the key decisions (and options) faced by the patient and provider; (ii) how the
new technology should change the pathway; (iii) which proximal demand and supply factors may constrain
the use of the technology; and (iv) which interventions may be required to address the demand and supply
constraints. For example, mRDTs should extend access to malaria testing and should reduce the number
of febrile patients who unnecessarily receive anti-malarials. However, these outcomes may be constrained
by the knowledge and preferences of both patients and providers, by patients’ ability to access and pay
for care, and by whether mRDTs, anti-malarials and treatments for non-malaria febrile illnesses are in stock.
Table II has been used in practice. Many of the demand and supply constraints listed here were identiﬁed
when designing interventions to support the rollout of mRDTs in Cameroon and were underpinned by a
theory of change evaluation and formative research (Achonduh et al., 2014). The ﬁnal column lists activities
to address these demand and supply constraints. In Cameroon, the interventions focused on provider knowl-
edge and behaviour (Mbacham et al., 2014; Mangham-Jefferies et al., 2014), although elsewhere, activities
have aimed to raise community awareness of mRDTs (Onwujekwe et al., 2015) or subsidise the cost of
RDTs (Chen et al., 2015).
It should also be noted that we do not recommend that the process of developing Table II is one conducted
by the economic evaluator alone. Deﬁning the intervention to introduce a new technology should be a multi-
stakeholder process. It is feasible for economists to work with programme/technology experts to arrive at an
outlined Table II before embarking on the model and cost-effectiveness analysis design (Onwujekwe et al.,
2015). It should also be noted that the resulting intervention may not address all constraints. Some activities
may still be considered by stakeholders as areas to address during implementation. Even in this case, our frame-
work encourages the researcher to consider the full cost of those activities that are agreed and to understand
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where the case pathway should be constrained in their analysis, even if the implementation of activities to ad-
dress constraints is postponed.
4. APPLYING THE CONCEPTUAL FRAMEWORK
When considering how to account for or address demand and supply constraints, the potential gains from
avoiding sub-optimal investment decisions must be weighed against the risk of delaying introduction of tech-
nologies with high beneﬁts by waiting for new evidence to emerge from more complex economic analyses.
While it may be feasible to work through the framework a priori, the data required to explore such a framework
empirically are potentially immense. We identify in the succeeding discussions several approaches to expedite
and support the application of this framework in different analytical situations.
4.1. Economic evaluations alongside early trials
Work on transferability from HICs identiﬁes various options for using trial data in economic evaluations either
when individual patient-level data are available or when the trial took place in the country of interest (Manca
and Willan, 2006). In the majority of cases of new technology adoption in LMICs, however, neither of these
two situations exists. Nevertheless, early trials of new technologies may still offer some opportunities to inform
economic evaluations incorporating constraints. Many trials of new technologies in LMICs are multi-centre and
thus provide scope to identify and collect data on location-speciﬁc constraints. However, opportunities may be
limited as the research process masks a number of constraints that would be observed elsewhere. Some argue
that trial sites could be selected to represent the range of settings into which the new technology may be placed,
incorporating any prior knowledge about key demand and supply constraints to improve representativeness
(Gheorghe et al., 2014). However, given the shortage of ‘trial ready’ sites in LMICs, and practical issues such
as distance and transportation to and from sites in LMICs, there may be a substantial trade-off between speed
and expense of trial start-up and ensuring that sites are representative.
Despite these limitations, at the very least, detailed descriptive reporting of the cost to ensure the implemen-
tation of both the standard of care and the intervention in trials should become standard practice. This would not
only help deﬁne the intervention but may also provide some information to estimate cost for other settings. This
recommendation is supported by the literature on the methodological implications of evaluating complex inter-
ventions, which emphasises the need for detailed and standardised reporting about the nature of the intervention
and the implementation process (Shiell et al., 2008).
In HICs, considerable attention has been placed on the analysis of patient-level data from trials to explore
heterogeneity across locations and individuals (Grieve et al., 2005; Gomes et al., 2012). Where constraints
are likely to operate at a sub-group or individual level, this additional data may add considerable insight. How-
ever, to date, there have been few trial-based cost-effectiveness analyses that report patient-level data on costs
and cost-effectiveness from LMICs. This is likely to be due in part to the substantial costs of data collection
involved, where routine systems for resource use are non-existent. Nonetheless, work is beginning to emerge
in this area (Barton et al., 2013; Mangham-Jefferies et al., 2014), and this approach offers the promise of
adding critical insight into a number of constraints, most notably, demand constraints that may operate at an
individual level.
4.2. Adapting model-based economic evaluations to consider supply and demand
Given the substantial limitations of trials, it is likely that for some time to come, analysts will continue to use
both trial data and models to predict the cost-effectiveness of new technologies in LMICs. In this case, there are
several approaches that may be considered. The ﬁrst option is perhaps the most intensive, viewing demand and
supply constraints with the same importance and rigour as any other determinant of cost-effectiveness incorpo-
rated in a model. This approach would involve applying our framework and conducting a systematic review on
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the inﬂuence of supply and demand constraints on key pathway probabilities and conducting a wide range of
sensitivity analyses. This would serve the purpose of further deﬁning which constraints are most important and
could help focus activities to address these constraints.
However, the data scarcity around many of these constraints in LMICs means that populating models with
plausible data may be problematic. For example, in our case studies, there was very little prior data available on the
levels of presumptive treatment in TB (Theron et al., 2014a). Even if the presumptive treatment rate is identiﬁed as
a key determinant of cost-effectiveness, it is hard to adjust for presumptive treatment rates in any particular loca-
tion. It may, however, be feasible to collect additional data as part of model-based evaluations, rather than solely
rely on systematic reviews. For example, it may be possible to estimate the costs of activities to address constraints
from other new technologies within the same country and conduct small observational studies in areas like clini-
cian behaviour. Such studies may have the wider beneﬁt of ensuring results resonate with decision makers, who
may have priors from previous experiences regarding the ‘real’ costs of implementation in their setting.
Where the literature indicates a constraint may be important but no local data are available, we recommend
at the very least that the uncertainty associated with the constraint be communicated with decision makers.
There are several examples of this approach emerging in the literature. Recent work by Gomez et al. models
shortened TB drugs regimens in a set of scenarios where full guideline adherence by healthcare providers
and patients is compared with ‘real world’ scenarios (Gomez et al., 2015). Another approach to explore con-
straints is ‘cascade’ modelling (Hallett and Eaton, 2013), which models the cost-effectiveness taking into ac-
count different levels of adherence to each key decision point along the case pathway. The speciﬁc costs and
effectiveness of bundles of ‘enabling’ interventions to improve key decision points in the cascade may then
be explored. A threshold analysis can then also be used to identify maximum levels of investment to address
constraints to the care pathway.
A further emerging approach is to link epidemiological models with bespoke economic or health system
models analysing demand and/or supply constraints in a single analytical frame. For example, in one of the
Xpert studies cited previously, Lin et al. (2011) linked the results of a setting-speciﬁc operational model
parameterised with local health facility data on patient ﬂows with a TB transmission model to investigate the
inﬂuence of capacity constraints on the cost-effectiveness of Xpert. On the demand side, another paper in this
supplement (Terris-Prestholt et al., 2016) links the results of discrete choice experiments and new technology
uptake models with economic evaluations.
4.3. Economic evaluations as part of impact evaluations
The preceding approaches may assist researchers to predict cost-effectiveness prior to new technology intro-
duction. However, substantial implementation research may still be required to understand the full inﬂuence
of demand and supply factors on the cost-effectiveness of new technologies in LMICs as technologies are
rolled out. Economic evaluations alongside implementation research or after scale-up remain scarce. Imple-
mentation research-based economic evaluations should be encouraged in order to provide further empirical
evidence and deeper understanding of key constraints when assessing the cost-effectiveness of introducing
new technologies globally.
5. CONCLUSION
In conclusion, we argue that economic evaluations of new technologies in LMICs should take a complex inter-
vention perspective and routinely consider demand and supply constraints. If demand and supply constraints
are not considered rigorously, local decision makers may consider that the economic evaluations are not rele-
vant to their local context, and scarce resources may be allocated away from more cost-effective interventions.
Proposing this paradigm shift, in terms of deﬁning an ‘intervention’ but considering the substantial empirical
challenge, we present a conceptual framework, examples of the framework’s application and discuss feasible
INCORPORATING DEMAND AND SUPPLY CONSTRAINTS IN ECONOMIC EVALUATIONS 111
© 2016 The Authors. Health Economics published by John Wiley & Sons Ltd. Health Econ. 25(Suppl. 1): 95–115 (2016)
DOI: 10.1002/hec
approaches. We recommend that considering these constraints explicitly be seen as standard ‘best practice’ in
economic evaluations in LMICs, even if the analysis remains partial given the substantial analytical and data
challenges. We recommend that demand and supply constraints be considered from the earliest stages of the
decision process, and that they be incorporated, applied and evaluated throughout the technology adoption
process, with at least as much rigour as epidemiological and price heterogeneity.
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